Vyant Bio, Inc.
VYNTDelisted May 4, 2023- Industry
- Services-Medical Laboratories
- SEC CIK
- 0001349929
Vyant Bio, Inc. was delisted on May 4, 2023; its insiders filed their last Form 4 on Feb 27, 2023; 17 institutions reported holding it in 13F filings for Q1 2023, worth $136.8K in total; no superinvestor held it.
13F holders, Q1 2023
Institutional positions in Vyant Bio, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
VYNT is no longer listed, so this page shows Q1 2023. 13F filings for later quarters list far fewer holders.
- Institutional holders
- 17
- 0 vs. Q4 2022
- Shares held
- 237.2K
- −81.0K (−25.5%) vs. Q4 2022
- Total value
- $136.8K
- −$85.3K (−38.4%) vs. Q4 2022
- New holders
- 3
- 4 more added
- Sold out
- 3
- 3 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VYNT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 1 | $1 |
| Q1 2023 | 17 | $136.8K |
| Q4 2022 | 17 | $222.1K |
| Q3 2022 | 26 | $949.3K |
| Q2 2022 | 21 | $1.47M |
| Q1 2022 | 23 | $2.54M |
| Q4 2021 | 27 | $3.12M |
| Q3 2021 | 23 | $5.27M |
| Q2 2021 | 29 | $8.41M |
| Q1 2021 | 18 | $2.96M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Vyant Bio, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 47,256 | $27.4K | 0.00% | −98,463−67.6% | Reduced |
| Geode Capital Management, LLC | 38,820 | $22.5K | 0.00% | 00.0% | Unchanged |
| Mayo Clinic | 27,742 | $16.1K | 0.01% | 00.0% | Unchanged |
| BlackRock Inc. | 26,558 | $15.4K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 22,419 | $13.0K | 0.00% | +22,419 | New |
| Susquehanna International Group, LLP | 20,001 | $11.6K | 0.00% | +20,001 | New |
| State Street Corp | 15,038 | $8.72K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 13,820 | $8.00K | 0.00% | −500−3.5% | Reduced |
| Virtu Financial LLC | 12,521 | $7.00K | 0.00% | +953+8.2% | Added |
| UBS Group AG | 5,463 | $3.17K | 0.00% | +508+10.3% | Added |
| US Bancorp | 4,962 | $2.88K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 2,478 | $1.00K | 0.00% | +2,478 | New |
| Wells Fargo & Company | 31 | $18 | 0.00% | +1+3.3% | Added |
| Advisor Group Holdings, Inc. | 24 | $14 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 9 | $5 | 0.00% | −324−97.3% | Reduced |
| Barclays PLC | 3 | $2 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 33 | $0 | 0.00% | +30+1,000.0% | Added |
| HRT Financial LP | 0 | $0 | 0.00% | −16,911−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −11,224−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −3−100.0% | Sold out |